-
公开(公告)号:US20070026029A1
公开(公告)日:2007-02-01
申请号:US10571469
申请日:2004-09-13
申请人: Frank Mattner , Walter Schmidt
发明人: Frank Mattner , Walter Schmidt
IPC分类号: A61K39/395 , A61F2/02
CPC分类号: G01N33/6896 , A61M1/3472 , A61M1/3486 , A61M1/3679
摘要: The invention relates to an apharesis device for use in the treatment of Alzheimer patients. Said device comprises a solid support with which a flow of blood or plasma can be contacted.
摘要翻译: 本发明涉及一种用于治疗阿尔茨海默病患者的脱水装置。 所述装置包括固体支持物,血液或血浆的流动可以与之接触。
-
公开(公告)号:US20060216691A1
公开(公告)日:2006-09-28
申请号:US10512885
申请日:2003-08-27
申请人: Michael Buschle , Andre Habel , Christoph Klade , Frank Mattner , Oleksandr Otava , Oresta Vytvytska , Wolfgang Zauner , Sandra Zinke , Helen Kirlappos
发明人: Michael Buschle , Andre Habel , Christoph Klade , Frank Mattner , Oleksandr Otava , Oresta Vytvytska , Wolfgang Zauner , Sandra Zinke , Helen Kirlappos
CPC分类号: C07K7/06 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/292 , A61K2039/525 , A61K2039/57 , C07K7/08 , C07K14/005 , C07K2319/00 , C12N2710/16122 , C12N2760/16122 , C12N2770/24222 , C12N2770/24234 , G01N2500/04 , Y10S930/223
摘要: Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterising the HCV-peptide from said complex.
摘要翻译: 描述了分离具有与MHC / HLA分子的结合能力的丙型肝炎病毒肽(HP)或包含所述HCV-肽和所述MHC / HLA分子的复合物的方法,其特征在于以下步骤: - 提供HCV池 肽,所述池包含结合所述MHC / HLA分子的HCV-肽和不结合所述MHC / HLA分子的HCV-肽, - 用所述HCV-肽池接触所述MHC / HLA分子,由此HCV- 具有与所述MHC / HLA分子的结合能力的肽与所述MHC / HLA分子结合,形成包含所述HCV-肽和所述MHC / HLA分子的复合物, - 检测并任选地将所述复合物与所述HCV-肽分离 不结合所述MHC / HLA分子并任选地从所述复合物中分离和表征HCV-肽。
-
公开(公告)号:US20060111301A1
公开(公告)日:2006-05-25
申请号:US10540551
申请日:2004-01-13
申请人: Frank Mattner
发明人: Frank Mattner
IPC分类号: A61K38/08
CPC分类号: C07K14/4711 , A61K38/08 , A61K38/10 , A61K38/1709 , C07K7/06
摘要: The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 is an amino acid, except of C, X6 is an amino acid, except of C, and wherein X1X2X3X4X5X6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal Aβ42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.
摘要翻译: 本发明涉及包含以下氨基酸序列X 1,X 2,X 3,X 4,N 2的化合物的用途 其中X 1是除C以外的氨基酸,X 2是一个 氨基酸除C外,X 3是除C以外的氨基酸,X 4是氨基酸,除了C,X 5, SUB>是除C以外的氨基酸,X 6是除C以外的氨基酸,其中X 1 X 2 X X 3×4×5×6不是DAEFRH,所述具有对抗体的结合能力的化合物是特异性的 对于天然N末端Abeta42序列DAEFRH,其具有对所述抗体的结合能力的5聚体对于天然N末端Aβ42序列DAEFRH是特异性的,用于制备阿尔茨海默氏病疫苗。
-
公开(公告)号:US20050063978A1
公开(公告)日:2005-03-24
申请号:US10399442
申请日:2001-10-18
申请人: Jorg Fritz , Frank Mattner , Wolfgang Zauner , Eszter Nagy , Michael Buschle
发明人: Jorg Fritz , Frank Mattner , Wolfgang Zauner , Eszter Nagy , Michael Buschle
CPC分类号: C07K7/06 , A61K39/0011 , A61K39/39 , A61K2039/55516 , Y02A50/412
摘要: The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1—XZXZNXZX—R2, whereby N is a whole number between 3 and 7, preferably 5, x is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independantly one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X—R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for the preparation of an adjuvant for enhancing the immune response to at least one antigen.
摘要翻译: 本发明涉及包含至少一种抗原和包含序列R1-XZXZNXZX-R2的肽的疫苗,其中N为3至7之间的整数,优选为5,x为带正电荷的天然和/或非天然 氨基酸残基,Z是选自L,V,I,F和/或W的氨基酸残基,R 1和R 2独立地选自-H,-NH 2, -COCH 3,-COH,具有多达20个氨基酸残基的肽或肽反应性基团或具有或不具有肽的肽接头; X-R2也可以是C末端氨基酸残基的酰胺,酯或硫酯,以及所述肽用于制备用于增强对至少一种抗原的免疫应答的佐剂的用途。
-
-
-